PL3260454T3 - Związek skondensowanej pirymidyny lub jego sól - Google Patents

Związek skondensowanej pirymidyny lub jego sól

Info

Publication number
PL3260454T3
PL3260454T3 PL16844411T PL16844411T PL3260454T3 PL 3260454 T3 PL3260454 T3 PL 3260454T3 PL 16844411 T PL16844411 T PL 16844411T PL 16844411 T PL16844411 T PL 16844411T PL 3260454 T3 PL3260454 T3 PL 3260454T3
Authority
PL
Poland
Prior art keywords
salt
pyrimidine compound
condensed pyrimidine
condensed
compound
Prior art date
Application number
PL16844411T
Other languages
English (en)
Inventor
Isao Miyazaki
Tadashi Shimamura
Masanori Kato
Hidenori Fujita
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL3260454T3 publication Critical patent/PL3260454T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL16844411T 2015-09-08 2016-09-07 Związek skondensowanej pirymidyny lub jego sól PL3260454T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015177073 2015-09-08
EP16844411.5A EP3260454B1 (en) 2015-09-08 2016-09-07 Condensed pyrimidine compound or salt thereof
PCT/JP2016/076354 WO2017043550A1 (ja) 2015-09-08 2016-09-07 縮合ピリミジン化合物又はその塩

Publications (1)

Publication Number Publication Date
PL3260454T3 true PL3260454T3 (pl) 2021-11-22

Family

ID=58239818

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16844411T PL3260454T3 (pl) 2015-09-08 2016-09-07 Związek skondensowanej pirymidyny lub jego sól

Country Status (20)

Country Link
US (4) US10233189B2 (pl)
EP (1) EP3260454B1 (pl)
JP (1) JP6113379B1 (pl)
KR (1) KR102058366B1 (pl)
CN (1) CN108026101B (pl)
AU (1) AU2016319525C1 (pl)
CA (1) CA2996682C (pl)
ES (1) ES2877537T3 (pl)
IL (1) IL257306B (pl)
MA (1) MA41559A (pl)
MX (1) MX390503B (pl)
MY (1) MY192184A (pl)
NZ (1) NZ739893A (pl)
PH (1) PH12017502407B1 (pl)
PL (1) PL3260454T3 (pl)
RU (1) RU2729636C2 (pl)
SG (1) SG11201800135WA (pl)
TW (1) TWI675840B (pl)
WO (1) WO2017043550A1 (pl)
ZA (1) ZA201800218B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
ES2775751T3 (es) 2016-02-23 2020-07-28 Taiho Pharmaceutical Co Ltd Nuevo compuesto de pirimidina condensada o sal del mismo
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
AU2018322286B2 (en) 2017-08-21 2022-03-10 Taiho Pharmaceutical Co., Ltd. Fusion protein of DCTN1 protein with RET protein
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
BR112020018383A2 (pt) 2018-04-05 2020-12-29 Merck Patent Gmbh Compostos heteroarílicos como inibidores da irak tipo ii e usos dos mesmos
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
MX2023005990A (es) * 2020-11-20 2023-06-07 Taiho Pharmaceutical Co Ltd Agente terapeutico antitumoral que migra al cerebro, que contiene como ingrediente activo un compuesto de pirimidina fusionada.
CA3234317A1 (en) 2021-10-22 2023-12-14 Wa Xian Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
US5665721A (en) 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
CN1925855B (zh) * 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
EP1797054A2 (en) 2004-08-02 2007-06-20 OSI Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
EP1968979A2 (en) * 2005-12-08 2008-09-17 Abbott Laboratories 9-membered heterobicyclic compounds as inhibitors of protein kinases
SG10201508035TA (en) * 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
EP2981613A4 (en) 2013-02-22 2016-11-02 Boris C Bastian FUSION POLYNUCLEOTIDES AND FUSION POLYPEPTIDES RELATED TO CANCER AND IN PARTICULAR TO MELANOMA AND USES THEREOF AS THERAPEUTIC AND DIAGNOSTIC OBJECTIVES
JP6397897B2 (ja) * 2013-05-14 2018-09-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ピロロ[2,3−d]ピリミジン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
WO2015022926A1 (ja) 2013-08-12 2015-02-19 大鵬薬品工業株式会社 新規な縮合ピリミジン化合物又はその塩
WO2015078417A1 (zh) 2013-11-29 2015-06-04 四川好医生药业集团有限公司 吡咯并嘧啶化合物及其在制备降血糖药物中的用途
JP2015205555A (ja) 2014-04-18 2015-11-19 日立オートモティブシステムズ株式会社 組込制御システム
DK3345907T3 (da) 2015-09-01 2020-06-22 Taiho Pharmaceutical Co Ltd Pyrazolo[3,4-d]pyrimidinforbindelser eller salte deraf
ES2775751T3 (es) 2016-02-23 2020-07-28 Taiho Pharmaceutical Co Ltd Nuevo compuesto de pirimidina condensada o sal del mismo

Also Published As

Publication number Publication date
CN108026101A (zh) 2018-05-11
EP3260454B1 (en) 2021-06-09
EP3260454A1 (en) 2017-12-27
CN108026101B (zh) 2020-06-26
AU2016319525A1 (en) 2018-01-25
US10233189B2 (en) 2019-03-19
NZ739893A (en) 2019-07-26
US20200270260A1 (en) 2020-08-27
US20180009817A1 (en) 2018-01-11
TWI675840B (zh) 2019-11-01
KR20180042368A (ko) 2018-04-25
RU2018112252A3 (pl) 2019-10-09
US11236096B2 (en) 2022-02-01
AU2016319525B2 (en) 2019-01-31
WO2017043550A1 (ja) 2017-03-16
CA2996682C (en) 2021-01-12
MA41559A (fr) 2017-12-26
KR102058366B1 (ko) 2019-12-23
EP3260454A4 (en) 2018-02-21
ES2877537T3 (es) 2021-11-17
PH12017502407A1 (en) 2018-06-25
MX390503B (es) 2025-03-20
JP6113379B1 (ja) 2017-04-12
US20190092776A1 (en) 2019-03-28
RU2729636C2 (ru) 2020-08-11
MX2018002889A (es) 2018-06-18
ZA201800218B (en) 2019-06-26
AU2016319525C1 (en) 2019-07-25
HK1254983A1 (zh) 2019-08-02
IL257306B (en) 2021-07-29
MY192184A (en) 2022-08-05
US10787457B2 (en) 2020-09-29
RU2018112252A (ru) 2019-10-09
JPWO2017043550A1 (ja) 2017-09-07
CA2996682A1 (en) 2017-03-16
TW201716412A (zh) 2017-05-16
US20200270261A1 (en) 2020-08-27
BR112018000698A2 (pt) 2018-09-18
PH12017502407B1 (en) 2018-06-25
US11014930B2 (en) 2021-05-25
IL257306A (en) 2018-03-29
SG11201800135WA (en) 2018-02-27

Similar Documents

Publication Publication Date Title
ZA201905332B (en) Novel condensed pyrimidine compound or salt thereof
PL3260454T3 (pl) Związek skondensowanej pirymidyny lub jego sól
SG11201802832UA (en) Pyrimidine compound
PL3381896T3 (pl) Związek bifenylowy lub jego sól
PT3357922T (pt) Composto de pirimidina ou piridopiridona e sua aplicação
IL250022A0 (en) New converted pyrimidine compounds
SG11201604954YA (en) Novel tetrahydropyridopyrimidine compound or salt thereof
EP3372588A4 (en) pyrimidine
GB2536673B (en) Evaporator
SG10201912270PA (en) Condensed heterocyclic compound
EP3381916A4 (en) CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF
IL258791A (en) Condensed heterocyclic compound
GB201701939D0 (en) Salt
AP2016009506A0 (en) Pyrimidine compound
SI3630729T1 (sl) Pirimidinska spojina
GB2537392B (en) Improved evaporator
HUE058181T2 (hu) Subsztituált guanidin vegyület